E-ISSN 2231-3206
 

Case Report


An unusual pediatric case of brand - specific vancomycin rash

Sarath Sudheendran, Prajakta Kolhe, Palak Agrawal, Rahul Kunkulol.


Abstract
Background:
Vancomycin, a glycopeptide antibiotic, is primarily indicated for resistant Gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA). While infusion-related reactions such as “Red Man Syndrome” are well recognized, delayed cutaneous hypersensitivity reactions, though uncommon, may present diagnostic and therapeutic challenges in pediatric patients. Awareness of such reactions is essential to prevent unnecessary morbidity and ensure safe therapeutic continuation.

Case Description:
A child on intravenous vancomycin therapy developed erythematous maculopapular rashes localized to the face on the 5th day of treatment. There was no mucosal or systemic involvement, and hematological and biochemical parameters were normal. The rash subsided promptly after substitution of the initial vancomycin brand with an alternative formulation, along with supportive care using antihistamines and emollients. Causality assessment using the World Health Organization–Uppsala Monitoring Centre (WHO-UMC) criteria categorized the event as “probable”.

Conclusion:
This case underscores the importance of recognizing formulation-specific reactions as a possible, though rare, cause of vancomycin-induced cutaneous ADRs. Thorough pharmacovigilance reporting and post-marketing surveillance are essential to validate such observations.

Key words: Vancomycin; Adverse drug reaction; Maculopapular rash; Pharmacovigilance; Pediatrics.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Sarath Sudheendran
Articles by Prajakta Kolhe
Articles by Palak Agrawal
Articles by Rahul Kunkulol
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Sudheendran S, Kolhe P, Agrawal P, Kunkulol R. An unusual pediatric case of brand - specific vancomycin rash. Natl J Physiol Pharm Pharmacol. 2025; 15(6): 439-442. doi:10.5455/NJPPP.2025.v15.i6.20


Web Style

Sudheendran S, Kolhe P, Agrawal P, Kunkulol R. An unusual pediatric case of brand - specific vancomycin rash. https://www.njppp.com/?mno=279248 [Access: December 20, 2025]. doi:10.5455/NJPPP.2025.v15.i6.20


AMA (American Medical Association) Style

Sudheendran S, Kolhe P, Agrawal P, Kunkulol R. An unusual pediatric case of brand - specific vancomycin rash. Natl J Physiol Pharm Pharmacol. 2025; 15(6): 439-442. doi:10.5455/NJPPP.2025.v15.i6.20



Vancouver/ICMJE Style

Sudheendran S, Kolhe P, Agrawal P, Kunkulol R. An unusual pediatric case of brand - specific vancomycin rash. Natl J Physiol Pharm Pharmacol. (2025), [cited December 20, 2025]; 15(6): 439-442. doi:10.5455/NJPPP.2025.v15.i6.20



Harvard Style

Sudheendran, S., Kolhe, . P., Agrawal, . P. & Kunkulol, . R. (2025) An unusual pediatric case of brand - specific vancomycin rash. Natl J Physiol Pharm Pharmacol, 15 (6), 439-442. doi:10.5455/NJPPP.2025.v15.i6.20



Turabian Style

Sudheendran, Sarath, Prajakta Kolhe, Palak Agrawal, and Rahul Kunkulol. 2025. An unusual pediatric case of brand - specific vancomycin rash. National Journal of Physiology, Pharmacy and Pharmacology, 15 (6), 439-442. doi:10.5455/NJPPP.2025.v15.i6.20



Chicago Style

Sudheendran, Sarath, Prajakta Kolhe, Palak Agrawal, and Rahul Kunkulol. "An unusual pediatric case of brand - specific vancomycin rash." National Journal of Physiology, Pharmacy and Pharmacology 15 (2025), 439-442. doi:10.5455/NJPPP.2025.v15.i6.20



MLA (The Modern Language Association) Style

Sudheendran, Sarath, Prajakta Kolhe, Palak Agrawal, and Rahul Kunkulol. "An unusual pediatric case of brand - specific vancomycin rash." National Journal of Physiology, Pharmacy and Pharmacology 15.6 (2025), 439-442. Print. doi:10.5455/NJPPP.2025.v15.i6.20



APA (American Psychological Association) Style

Sudheendran, S., Kolhe, . P., Agrawal, . P. & Kunkulol, . R. (2025) An unusual pediatric case of brand - specific vancomycin rash. National Journal of Physiology, Pharmacy and Pharmacology, 15 (6), 439-442. doi:10.5455/NJPPP.2025.v15.i6.20